• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).对《评估新型胰高血糖素样肽-1类似物利拉鲁肽在阿尔茨海默病中的作用：一项随机对照试验的研究方案（ELAD研究）》的勘误
Trials. 2020 Jul 19;21(1):660. doi: 10.1186/s13063-020-04608-4.
2
GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.胰高血糖素样肽-1（GLP-1）受体存在于人类大脑的顶叶皮质、下丘脑和髓质中，并且GLP-1类似物利拉鲁肽会改变糖尿病患者中与极具吸引力的食物线索相关的大脑活动：一项交叉、随机、安慰剂对照试验。
Diabetologia. 2016 May;59(5):954-65. doi: 10.1007/s00125-016-3874-y. Epub 2016 Feb 1.
3
Correction to: Routine versus on demand removal of the syndesmotic screw; a protocol for an international randomised controlled trial (RODEO-trial).对《下胫腓螺钉常规取出与按需取出；一项国际随机对照试验方案（RODEO试验）》的勘误
BMC Musculoskelet Disord. 2020 Aug 5;21(1):520. doi: 10.1186/s12891-020-03516-7.
4
Correction to: Investigating the non-specific effects of BCG vaccination on the innate immune system in Ugandan neonates: study protocol for a randomised controlled trial.对《研究乌干达新生儿中卡介苗接种对先天免疫系统的非特异性影响：一项随机对照试验的研究方案》的勘误
Trials. 2020 Aug 10;21(1):707. doi: 10.1186/s13063-020-04594-7.
5
Correction to: Fasting in diabetes treatment (FIT) trial: study protocol for a randomised, controlled, assessor-blinded intervention trial on the effects of intermittent use of a fasting-mimicking diet in patients with type 2 diabetes.对以下内容的修正：糖尿病治疗中的禁食（FIT）试验：一项关于间歇性使用模拟禁食饮食对2型糖尿病患者影响的随机、对照、评估者盲法干预试验的研究方案。
BMC Endocr Disord. 2020 Nov 4;20(1):164. doi: 10.1186/s12902-020-00635-z.
6
Correction to: One Plus One Equals Two-will that do? A trial protocol for a Swedish multicentre randomised controlled trial to evaluate a clinical practice to reduce severe perineal trauma.更正：一加一等于二——这样可以吗？一项瑞典多中心随机对照试验的试验方案，旨在评估一种减少严重会阴创伤的临床实践。
Trials. 2020 Dec 2;21(1):993. doi: 10.1186/s13063-020-04936-5.
7
Correction to: Task sharing for the care of severe mental disorders in a low-income country (TaSCS): study protocol for a randomised, controlled, non-inferiority trial.对《低收入国家严重精神障碍护理任务分担（TaSCS）：一项随机对照非劣效性试验的研究方案》的勘误
Trials. 2020 Oct 6;21(1):829. doi: 10.1186/s13063-020-04776-3.
8
Correction to: Protocol for a randomised controlled trial to investigate the effect of home- and gym-based resistance exercise training on glycaemic control, body composition and muscle strength.对以下内容的更正：一项随机对照试验的方案，该试验旨在研究居家和健身房进行的抗阻运动训练对血糖控制、身体成分和肌肉力量的影响。
Trials. 2020 Jul 15;21(1):650. doi: 10.1186/s13063-020-04597-4.
9
Correction to: Persistent physical symptoms reduction intervention: a system change and evaluation in secondary care (PRINCE secondary) - a CBT-based transdiagnostic approach: study protocol for a randomised controlled trial.对以下内容的更正：持续性身体症状减轻干预：二级医疗中的系统变革与评估（PRINCE二级）——一种基于认知行为疗法的跨诊断方法：一项随机对照试验的研究方案。
BMC Psychiatry. 2020 Aug 12;20(1):403. doi: 10.1186/s12888-020-02811-w.
10
Correction to: Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial.对以下内容的更正：沙格司亭治疗新型冠状病毒肺炎所致急性低氧性呼吸衰竭患者（SARPAC）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 22;21(1):554. doi: 10.1186/s13063-020-04520-x.

引用本文的文献

1
Incretin Hormones GLP-1 and GIP Normalize Energy Utilization and Reduce Inflammation in the Brain in Alzheimer's Disease and Parkinson's Disease: From Repurposed GLP-1 Receptor Agonists to Novel Dual GLP-1/GIP Receptor Agonists as Potential Disease-Modifying Therapies.肠促胰岛素激素GLP-1和GIP使阿尔茨海默病和帕金森病患者大脑中的能量利用正常化并减轻炎症：从GLP-1受体激动剂的重新利用到新型GLP-1/GIP双受体激动剂作为潜在的疾病修饰疗法。
CNS Drugs. 2025 Sep 12. doi: 10.1007/s40263-025-01226-z.
2
Activation of AMPK by GLP-1R agonists mitigates Alzheimer-related phenotypes in transgenic mice.胰高血糖素样肽-1受体激动剂激活AMPK可减轻转基因小鼠的阿尔茨海默病相关表型。
Nat Aging. 2025 May 20. doi: 10.1038/s43587-025-00869-3.
3
A combination of midlife diabetes mellitus and the apolipoprotein E ε4 allele increase risk for cognitive decline.中年糖尿病和载脂蛋白Eε4等位基因相结合会增加认知能力下降的风险。
Front Aging Neurosci. 2022 Nov 17;14:1065117. doi: 10.3389/fnagi.2022.1065117. eCollection 2022.
4
Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment.胰高血糖素样肽-1（GLP-1）受体激动剂与神经炎症：对神经退行性疾病治疗的启示。
Pharmacol Res. 2022 Dec;186:106550. doi: 10.1016/j.phrs.2022.106550. Epub 2022 Nov 11.
5
Neuropsychological decrements in midlife type-2 diabetes are not associated with peripheral NLRP3 inflammasome responsiveness.中年 2 型糖尿病患者的神经认知功能下降与外周 NLRP3 炎性小体反应性无关。
Front Immunol. 2022 Oct 13;13:1021351. doi: 10.3389/fimmu.2022.1021351. eCollection 2022.
6
Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer's and Parkinson's diseases.胰高血糖素样肽1和葡萄糖依赖性促胰岛素多肽激素以及新型受体激动剂可保护阿尔茨海默病和帕金森病中的突触。
Front Synaptic Neurosci. 2022 Jul 27;14:955258. doi: 10.3389/fnsyn.2022.955258. eCollection 2022.
7
Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease.在阿尔茨海默病药物研发中针对全身代谢和线粒体生物能量学
Acta Pharm Sin B. 2022 Feb;12(2):511-531. doi: 10.1016/j.apsb.2021.06.014. Epub 2021 Jun 30.
8
Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control.胰岛素抵抗限制了 2 型糖尿病患者强化血糖控制后角膜神经的再生。
J Diabetes Investig. 2021 Nov;12(11):2002-2009. doi: 10.1111/jdi.13582. Epub 2021 Jun 19.

本文引用的文献

1
Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).评估新型胰高血糖素样肽-1类似物利拉鲁肽对阿尔茨海默病的影响：一项随机对照试验的研究方案（ELAD研究）。
Trials. 2019 Apr 3;20(1):191. doi: 10.1186/s13063-019-3259-x.

对《评估新型胰高血糖素样肽-1类似物利拉鲁肽在阿尔茨海默病中的作用：一项随机对照试验的研究方案（ELAD研究）》的勘误

Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).

作者信息

Femminella Grazia Daniela, Frangou Eleni, Love Sharon B, Busza Gail, Holmes Clive, Ritchie Craig, Lawrence Robert, McFarlane Brady, Tadros George, Ridha Basil H, Bannister Carol, Walker Zuzana, Archer Hilary, Coulthard Elizabeth, Underwood Ben R, Prasanna Aparna, Koranteng Paul, Karim Salman, Junaid Kehinde, McGuinness Bernadette, Nilforooshan Ramin, Macharouthu Ajay, Donaldson Andrew, Thacker Simon, Russell Gregor, Malik Naghma, Mate Vandana, Knight Lucy, Kshemendran Sajeev, Harrison John, Hölscher Christian, Brooks David J, Passmore Anthony Peter, Ballard Clive, Edison Paul

机构信息

Department of Medicine, Imperial College London, London, UK.

Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

出版信息

Trials. 2020 Jul 19;21(1):660. doi: 10.1186/s13063-020-04608-4.

DOI:10.1186/s13063-020-04608-4
PMID:32684162
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7370449/
Abstract

An amendment to this paper has been published and can be accessed via the original article.

摘要

本文的一篇修正已发表，可通过原始文章获取。